Journal article

Protocol and Rationale-The Efficacy of Minocycline as an Adjunctive Treatment for Major Depressive Disorder: A Double Blind, Randomised, Placebo Controlled Trial

Olivia May Dean, Michael Maes, Melanie Ashton, Lesley Berk, Buranee Kanchanatawan, Atapol Sughondhabirom, Sookjareon Tangwongchai, Chee Ng, Nathan Dowling, Gin S Malhi, Michael Berk

CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE | KOREAN COLL NEUROPSYCHOPHARMACOLOGY | Published : 2014

Abstract

While current pharmacotherapies are efficacious, there remain a clear shortfall between symptom remission and functional recovery. With the explosion in our understanding of the biology of these disorders, the time is ripe for the investigation of novel therapies. Recently depression is conceptualized as an immune-inflammatory and nitro-oxidative stress related disorder. Minocycline is a tetracycline antibiotic that has anti-inflammatory, pro-oxidant, glutamatergic, neurotrophic and neuroprotective properties that make it a viable target to explore as a new therapy. This double blind, randomised, placebo controlled adjunctive trial will investigate the benefits of 200 mg/day of minocycline t..

View full abstract

Grants

Funding Acknowledgements

The authors would like to acknowledge the support of the Brain and Behavior Foundation, the Australasian Society of Bipolar and Depressive Disorders and the Alfred Deakin Postdoctoral Research Fellowship. We would also like to acknowledge the service support of Barwon Health, Deakin University, The Melbourne Clinic, The University of Melbourne and Chulalongkorn University.